Pancreatic Cancer Research

ResearcherUniversitätsmedizin GöttingenActive in the last 2 years

Lukas Klein

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3725-068X; OpenAlex author ID A5046866105. Sources: OpenAlex.

Their work

Papers
10 (first author 4, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
52
Papers, trials and grants by year

2019: 1 paper · 2020: none · 2021: 1 paper · 2022: 2 papers · 2023: 2 papers · 2024: none · 2025: 2 papers · 2026: 2 papers

Papers 10

  1. Targeting addiction to HMGB2-driven transcriptional programs in pancreatic cancer. Co-author DOI 10.1016/j.celrep.2026.117649↗
  2. GSK3βhigh/NFATc1high subtype targeting overcomes therapy resistance in pancreatic cancer through transcriptional induction of homologous recombination repair. Co-author DOI 10.1136/gutjnl-2025-336227↗
  3. Spatial tumor immune heterogeneity facilitates subtype co-existence and therapy response in pancreatic cancer. Co-author DOI 10.1038/s41467-024-55330-7↗
  4. TP53 missense-specific transcriptional plasticity drives resistance against cell cycle inhibitors in pancreatic cancer. Co-author DOI 10.1126/sciadv.adu2339↗
  5. Neutrophil-derived complement factor P induces cytotoxicity in basal-like cells via caspase 3/7 activation in pancreatic cancer Co-author DOI 10.1101/2023.10.28.564512↗
  6. IL-17A-producing CD8+ T cells promote PDAC via induction of inflammatory cancer-associated fibroblasts. Co-author DOI 10.1136/gutjnl-2022-327855↗
  7. Mechanisms of PDAC subtype heterogeneity and therapy response. First author DOI 10.1016/j.trecan.2022.08.005↗
  8. Axon guidance receptor ROBO3 modulates subtype identity and prognosis via AXL-associated inflammatory network in pancreatic cancer. First author DOI 10.1172/jci.insight.154475↗
  9. TNF-α-producing macrophages determine subtype identity and prognosis via AP1 enhancer reprogramming in pancreatic cancer. First author DOI 10.1038/s43018-021-00258-w↗
  10. Stromal Features of the Primary Tumor Are Not Prognostic in Genetically Engineered Mice of Pancreatic Cancer. First author DOI 10.3390/cells9010058↗

Closest collaborators

The 25 strongest of 52 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shiv K. Singh · 9 shared papers, 2021–2026 · strength 1.53
  2. Volker Ellenrieder · 7 shared papers, 2019–2026 · strength 1.07
  3. Elisabeth Heßmann · 5 shared papers, 2021–2026 · strength 0.82
  4. Mengyu Tu · 5 shared papers, 2021–2025 · strength 0.67
  5. Laura Urbach · 4 shared papers, 2021–2025 · strength 0.64
  6. Elisa Espinet Espinet · 4 shared papers, 2021–2025 · strength 0.62
  7. Uday Kishore · 4 shared papers, 2021–2025 · strength 0.55
  8. Argyris Papantonis · 3 shared papers, 2021–2026 · strength 0.50
  9. Lena‐Christin Conradi · 2 shared papers, 2026 · strength 0.42
  10. Ulrich Sax · 2 shared papers, 2025–2026 · strength 0.42
  11. Rebecca Diya Samuel · 2 shared papers, 2025 · strength 0.40
  12. Andreas Trumpp · 3 shared papers, 2021–2025 · strength 0.40
  13. Muhammad Umair Latif · 2 shared papers, 2025–2026 · strength 0.39
  14. Albrecht Neeße · 3 shared papers, 2019–2022 · strength 0.32
  15. Adi Danieli‐Mackay · 2 shared papers, 2021–2026 · strength 0.31
  16. Niklas Krebs · 2 shared papers, 2022–2025 · strength 0.30
  17. Ellen Puré · 1 shared paper, 2022 · strength 0.22
  18. Gabriela Salinas Riester · 1 shared paper, 2026 · strength 0.22
  19. Tiago De Oliveira · 1 shared paper, 2026 · strength 0.22
  20. Emre Taylan Duman · 1 shared paper, 2026 · strength 0.22
  21. Matthias Dobbelstein · 1 shared paper, 2026 · strength 0.22
  22. Michael B. Ghadimi · 1 shared paper, 2025 · strength 0.22
  23. Ramona Schulz‐Heddergott · 1 shared paper, 2025 · strength 0.22
  24. Nelson Dusetti · 1 shared paper, 2025 · strength 0.22
  25. Steven A. Johnsen · 1 shared paper, 2026 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.